Assessing developability early in the discovery process for novel biologics
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Beyond potency, a good developability profile is a key attribute of a biological drug. Selecting and screening for such attributes early in the drug development process can save resources and avoid costly late-stage failures. Here, we review some of the most important developability properties that can be assessed early on for biologics. These include the influence of the source of the biologic, its biophysical and pharmacokinetic properties, and how well it can be expressed recombinantly. We furthermore present in silico, in vitro, and in vivo methods and techniques that can be exploited at different stages of the discovery process to identify molecules with liabilities and thereby facilitate the selection of the most optimal drug leads. Finally, we reflect on the most relevant developability parameters for injectable versus orally delivered biologics and provide an outlook toward what general trends are expected to rise in the development of biologics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566 · cited 1×
“Bringing a biologic from early discovery to a marketed product is an immensely expensive endeavor, with the average investment being further compounded by the high attrition rates in clinical development.(1) While the clinical success of a biologic ultimately depends on its safety and efficacy in human patients, the u…”
BackgroundDynamic personalities of proteins
Henzler-Wildman, K., & Kern, D. (2007) · Nature · doi:10.1038/nature06522 · Cited by 2,545
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
FcRn: the neonatal Fc receptor comes of age
Roopenian, D. C., & Akilesh, S. (2007) · Nature Reviews Immunology · doi:10.1038/nri2155 · Cited by 2,346
Biopharmaceutical benchmarks 2018
Walsh, G. (2018) · Nature Biotechnology · doi:10.1038/nbt.4305 · Cited by 978 · cited 1×
“Transient human expression systems are often preferred early on due to the ease and speed of production of workable product quantities,(227) while stable CHO cell lines are preferred for commercial production.(9) This change can cause profound differences in the product yield and quality MABS 9”
BackgroundBiophysical properties of the clinical-stage antibody landscape
Jain, T., Sun, T., Durand, S., Hall, A., Houston, N. R., Nett, J. H., Sharkey, B., Bobrowicz, B., Caffry, I., Yu, Y., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616408114 · Cited by 629 · cited 5×
“While the clinical success of a biologic ultimately depends on its safety and efficacy in human patients, the underlying properties of these endpoints include everything from drug potency, specificity, immunogenicity, and pharmacokinetics to biophysical behavior in vivo and during storage.(2,3) Moreover, with more adv…”
BackgroundInfluentialHuman antibodies from transgenic animals.
Lonberg, N. (2005) · Nature Biotechnology · doi:10.1038/nbt1135 · Cited by 434
Effects of Charge on Antibody Tissue Distribution and Pharmacokinetics
Boswell, C. A., Tesar, D. B., Mukhyala, K., Theil, F.-P., Fielder, P. J., & Khawli, L. A. (2010) · Bioconjugate Chemistry · doi:10.1021/bc100261d · Cited by 398
Five computational developability guidelines for therapeutic antibody profiling
Raybould, M. I. J., Marks, C., Krawczyk, K., Taddese, B., Nowak, J., Lewis, A. P., Bujotzek, A., Shi, J., & Deane, C. M. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810576116 · Cited by 357 · cited 3×
“These traits arise from biophysical properties such as surface charge, charge patches, isoelectric point, and hydrophobicity, and affect both FcRn binding, cellular transport, and in vivo performance.(80,168,169,183) Therefore, cellular assays mimicking these traits are vital, and may provide necessary data input for…”
BackgroundStapleton, N. M., Andersen, J. T., Stemerding, A. M., Bjarnarson, S. P., Verheul, R. C., Gerritsen, J., Zhao, Y., Kleijer, M., Sandlie, I., de Haas, M., et al. (2011) · Nature Communications · doi:10.1038/ncomms1608 · Cited by 286
Self-citation
Cited by
Bashour, H., Smorodina, E., Pariset, M., Zhong, J., Akbar, R., Chernigovskaya, M., Lê Quý, K., Snapkow, I., Rawat, P., Krawczyk, K., et al. (2024) · Communications Biology · doi:10.1038/s42003-024-06561-3 · Cited by 32
Self-citationTulika, T., Pedersen, R. W., Rimbault, C., Ahmadi, S., Rivera‐de‐Torre, E., Fernández‐Quintero, M. L., Loeffler, J. R., Bohn, M., Ljungars, A., Ledsgaard, L., et al. (2023) · Protein Science · doi:10.1002/pro.4821 · Cited by 11
Self-citationVidal-Henriquez, E., Holder, T., Lee, N. F., Pompe, C., & Teese, M. G. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.10.026 · Cited by 9
Metadata
- Authors
- Fernández-Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G., Grav, L. M., Kumar, S., Georges, G., Kettenberger, H., Liedl, K. R., Tessier, P. M., McCafferty, J., & Laustsen, A. H.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2023-02-23
- Volume
- 15
- Issue
- 1
- Pages
- 2171248-2171248
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W4321748896
- Cited by
- 99
- References
- 35
- FWCI
- 7.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Assessing developability early in the discovery process for novel biologics. https://app.cochat.ai/papers/10.1080/19420862.2023.2171248
- The paper
- Fernández-Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G., Grav, L. M., Kumar, S., Georges, G., Kettenberger, H., Liedl, K. R., Tessier, P. M., McCafferty, J., & Laustsen, A. H. (2023). Assessing developability early in the discovery process for novel biologics. mAbs. https://doi.org/10.1080/19420862.2023.2171248
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.